Study Stopped
Sponsor decision to deprioritize the dengue program
Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model
A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Assess the Antiviral Activity and Safety of AT-752 in a Dengue Human Challenge Model
1 other identifier
interventional
5
1 country
1
Brief Summary
This study will assess the safety and antiviral activity of AT-752 in healthy subjects in a Dengue Human Challenge Model
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_1
Started Apr 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 22, 2022
CompletedFirst Submitted
Initial submission to the registry
May 5, 2022
CompletedFirst Posted
Study publicly available on registry
May 9, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 16, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 16, 2023
CompletedApril 21, 2023
May 1, 2022
11 months
May 5, 2022
April 20, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Mean quantitative RNAemia (peak and duration and area under the plasma concentration versus time curve [AUC])
Day 2 until 28 days post virus inoculation
Study Arms (2)
AT-752
EXPERIMENTALAT-752 administered orally for 14 days
Placebo
PLACEBO COMPARATORMatching placebo administered orally for 14 days
Interventions
Eligibility Criteria
You may qualify if:
- Must agree to use protocol-specified methods of contraception
- Negative pregnancy test
- Willing to comply with the study requirements and to provide written informed consent
You may not qualify if:
- Pregnant or breastfeeding
- Abuse of drugs
- Other clinically significant medical conditions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Atea Study Site
Syracuse, New York, 13215, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 5, 2022
First Posted
May 9, 2022
Study Start
April 22, 2022
Primary Completion
March 16, 2023
Study Completion
March 16, 2023
Last Updated
April 21, 2023
Record last verified: 2022-05